Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 3008 | 2017 |
Cancer therapy shapes the fitness landscape of clonal hematopoiesis KL Bolton, RN Ptashkin, T Gao, L Braunstein, SM Devlin, D Kelly, M Patel, ... Nature genetics 52 (11), 1219-1226, 2020 | 468 | 2020 |
Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention MA Lowery, R Ptashkin, E Jordan, MF Berger, A Zehir, M Capanu, ... Clinical Cancer Research 24 (17), 4154-4161, 2018 | 436 | 2018 |
High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden R Benayed, M Offin, K Mullaney, P Sukhadia, K Rios, P Desmeules, ... Clinical Cancer Research 25 (15), 4712-4722, 2019 | 365 | 2019 |
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial YY Janjigian, SB Maron, WK Chatila, B Millang, SS Chavan, C Alterman, ... The Lancet Oncology 21 (6), 821-831, 2020 | 306 | 2020 |
SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas N Rekhtman, J Montecalvo, JC Chang, D Alex, RN Ptashkin, N Ai, ... Journal of Thoracic Oncology 15 (2), 231-247, 2020 | 223 | 2020 |
Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype MA Lowery, EJ Jordan, O Basturk, RN Ptashkin, A Zehir, MF Berger, ... Clinical Cancer Research 23 (20), 6094-6100, 2017 | 185 | 2017 |
Resistance to TRK inhibition mediated by convergent MAPK pathway activation E Cocco, AM Schram, A Kulick, S Misale, HH Won, R Yaeger, P Razavi, ... Nature medicine 25 (9), 1422-1427, 2019 | 183 | 2019 |
Respiratory syncytial virus utilizes a tRNA fragment to suppress antiviral responses through a novel targeting mechanism J Deng, RN Ptashkin, Y Chen, Z Cheng, G Liu, T Phan, X Deng, J Zhou, ... Molecular Therapy 23 (10), 1622-1629, 2015 | 163 | 2015 |
Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors RN Ptashkin, DL Mandelker, CC Coombs, K Bolton, Z Yelskaya, ... JAMA oncology 4 (11), 1589-1593, 2018 | 161 | 2018 |
Large chromosomal rearrangements during a long-term evolution experiment with Escherichia coli C Raeside, J Gaffé, DE Deatherage, O Tenaillon, AM Briska, RN Ptashkin, ... MBio 5 (5), 10.1128/mbio. 01377-14, 2014 | 140 | 2014 |
Clonal hematopoiesis is associated with risk of severe Covid-19 KL Bolton, Y Koh, MB Foote, H Im, J Jee, CH Sun, A Safonov, R Ptashkin, ... Nature communications 12 (1), 5975, 2021 | 105 | 2021 |
DNA methylation-based classification of sinonasal undifferentiated carcinoma S Dogan, V Vasudevaraja, B Xu, J Serrano, RN Ptashkin, HJ Jung, ... Modern Pathology 32 (10), 1447-1459, 2019 | 101 | 2019 |
Frequent IDH2 R172 mutations in undifferentiated and poorly‐differentiated sinonasal carcinomas S Dogan, DJ Chute, B Xu, RN Ptashkin, R Chandramohan, ... The Journal of pathology 242 (4), 400-408, 2017 | 95 | 2017 |
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS A Rose Brannon, G Jayakumaran, M Diosdado, J Patel, A Razumova, ... Nature communications 12 (1), 3770, 2021 | 93 | 2021 |
Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis T Gao, R Ptashkin, KL Bolton, M Sirenko, C Fong, B Spitzer, ... Nature communications 12 (1), 338, 2021 | 81 | 2021 |
Mammary analog secretory carcinoma of the thyroid gland: a primary thyroid adenocarcinoma harboring ETV6–NTRK3 fusion S Dogan, L Wang, RN Ptashkin, RR Dawson, JP Shah, EJ Sherman, ... Modern Pathology 29 (9), 985-995, 2016 | 80 | 2016 |
Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms SS Patel, C Ho, RN Ptashkin, S Sadigh, A Bagg, JT Geyer, ML Xu, ... Blood Advances 3 (9), 1540-1545, 2019 | 57 | 2019 |
The clinical management of clonal hematopoiesis: creation of a clonal hematopoiesis clinic KL Bolton, A Zehir, RN Ptashkin, M Patel, D Gupta, R Sidlow, ... Hematology/Oncology Clinics 34 (2), 357-367, 2020 | 47 | 2020 |
Fragment size analysis may distinguish clonal hematopoiesis from tumor-derived mutations in cell-free DNA F Marass, D Stephens, R Ptashkin, A Zehir, MF Berger, DB Solit, ... Clinical chemistry 66 (4), 616-618, 2020 | 40 | 2020 |